Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2018 May 9

PMID 29736194

Citations 17

Authors

Natacha Turck

Simone Eperon

Maria De Los Angeles Gracia

Aurelie Oberic

Mehrad Hamedani

Affiliations

Soon will be listed here.

Abstract

Background: Thyroid-associated orbitopathy (TAO) is the most common autoimmune disease of the orbit. It occurs more often in patients presenting with hyperthyroidism, characteristic of Graves' disease, but may be associated with hypothyroidism or euthyroidism. The diagnosis of TAO is based on clinical orbital features, radiological criteria, and the potential association with thyroid disease. To date, there is no specific marker of the orbital disease, making the early diagnosis difficult, especially if the orbital involvement precedes the thyroid dysfunction.

Summary: The goal of this review is to present the disease and combine the available data in the literature concerning investigation of TAO biomarkers.

Conclusions: Despite the progress done in the understanding of TAO disease, some important pieces are still missing. Typically, for the future, major efforts have to be done in the discovery of new biomarkers, validation of the suspected candidates on multicenter cohorts with standardized methodologies, and establishment of their clinical performances on the specific clinical application fields in order to improve not only the management of the TAO patients but also the therapeutic options and follow-up.

Citing Articles

The association of race with thyroid eye disease presentation and outcomes.

Wang D, Marous C, Celiker P, Deng W, Kristoferson E, Elsayed A Front Ophthalmol (Lausanne). 2024; 3:1309850.

PMID: 38983053 PMC: 11182153. DOI: 10.3389/fopht.2023.1309850.

Implementation of thyroid eye disease registry in Iran: rationale and research protocol.

Akbarian S, Sheikhtaheri A, Khorrami F, Ghahvechian H, Karimi N, Kashkouli M Orphanet J Rare Dis. 2024; 19(1):42.

PMID: 38321499 PMC: 10845661. DOI: 10.1186/s13023-024-03053-9.

Molecular Biomarkers in Thyroid Eye Disease: A Literature Review.

Ueland H, Neset M, Methlie P, Ueland G, Pakdel F, Rodahl E Ophthalmic Plast Reconstr Surg. 2023; 39(6S):S19-S28.

PMID: 38054982 PMC: 10697285. DOI: 10.1097/IOP.0000000000002466.

The Role of Interleukin-17A and NLRP3 Inflammasome in the Pathogenesis of Graves' Ophthalmopathy.

Lin C, Liao S, Wei Y Life (Basel). 2023; 13(4).

PMID: 37109536 PMC: 10141012. DOI: 10.3390/life13041007.

The significance of ophthalmological features in diagnosis of thyroid-associated ophthalmopathy.

Huang X, Tang W, Shen Y, He L, Tong F, Liu S Biomed Eng Online. 2023; 22(1):7.

PMID: 36739403 PMC: 9898900. DOI: 10.1186/s12938-023-01073-3.

References

Pinchera A, Liberti P, Martino E, Fenzi G, Grasso L, Rovis L . Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies. J Clin Endocrinol Metab. 1969; 29(2):231-8. DOI: 10.1210/jcem-29-2-231. View

Czarnywojtek A, Zgorzalewicz-Stachowiak M, Budny B, Wasko R, Florek E, Szczepanek E . The influence of radioiodine therapy on ocular changes and their relation to urine cotinine level in patients with Graves' Ophthalmopathy. Neuro Endocrinol Lett. 2013; 34(3):241-8. View

van Steensel L, Hooijkaas H, Paridaens D, van den Bosch W, Kuijpers R, Drexhage H . PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients. J Clin Endocrinol Metab. 2012; 97(6):E944-53. DOI: 10.1210/jc.2012-1020. View

Matheis N, Grus F, Breitenfeld M, Knych I, Funke S, Pitz S . Proteomics Differentiate Between Thyroid-Associated Orbitopathy and Dry Eye Syndrome. Invest Ophthalmol Vis Sci. 2015; 56(4):2649-56. DOI: 10.1167/iovs.15-16699. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

WERNER S . Modification of the classification of the eye changes of Graves' disease. Am J Ophthalmol. 1977; 83(5):725-7. DOI: 10.1016/0002-9394(77)90140-4. View

Tramontano D, Cushing G, Moses A, Ingbar S . Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG. Endocrinology. 1986; 119(2):940-2. DOI: 10.1210/endo-119-2-940. View

Kamijo K, Ishikawa K, Tanaka M . Clinical evaluation of 3rd generation assay for thyrotropin receptor antibodies: the M22-biotin-based ELISA initiated by Smith. Endocr J. 2005; 52(5):525-9. DOI: 10.1507/endocrj.52.525. View

Ezra D, Krell J, Rose G, Bailly M, Stebbing J, Castellano L . Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy. J Clin Pathol. 2012; 65(7):608-13. PMC: 7611799. DOI: 10.1136/jclinpath-2012-200719. View

10.

Mourits M, Koornneef L, Wiersinga W, Prummel M, Berghout A, van der Gaag R . Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 1989; 73(8):639-44. PMC: 1041835. DOI: 10.1136/bjo.73.8.639. View

11.

Saraci G, Treta A . Ocular changes and approaches of ophthalmopathy in basedow - graves- parry- flajani disease. Maedica (Bucur). 2011; 6(2):146-52. PMC: 3239395. View

12.

McCoy A, Kim D, Gillespie E, Atkins S, Smith T, Douglas R . Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells. J Clin Endocrinol Metab. 2014; 99(7):E1294-9. PMC: 4399483. DOI: 10.1210/jc.2013-3207. View

13.

Frydecka I, Daroszewski J, Suwalska K, Zoledziowska M, Tutak A, Slowik M . CTLA-4 (CD152) gene polymorphism at position 49 in exon 1 in Graves' disease in a Polish population of the Lower Silesian region. Arch Immunol Ther Exp (Warsz). 2004; 52(5):369-74. View

14.

Goh S, Ho S, Seah L, Fong K, Khoo D . Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves' disease differ and suggest ophthalmopathy is a multiantigenic disease. Clin Endocrinol (Oxf). 2004; 60(5):600-7. DOI: 10.1111/j.1365-2265.2004.02033.x. View

15.

van Steensel L, Paridaens D, van Meurs M, van Hagen P, van den Bosch W, Kuijpers R . Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves' ophthalmopathy. J Clin Endocrinol Metab. 2012; 97(3):E400-8. DOI: 10.1210/jc.2011-2697. View

16.

Eckstein A, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K . Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf). 2004; 61(5):612-8. DOI: 10.1111/j.1365-2265.2004.02143.x. View

17.

Lehmann G, Garcia-Bates T, Smith T, Feldon S, Phipps R . Regulation of Lymphocyte Function by PPARgamma: Relevance to Thyroid Eye Disease-Related Inflammation. PPAR Res. 2008; 2008:895901. PMC: 2266979. DOI: 10.1155/2008/895901. View

18.

Lim H, Back K, Kim H, Choi Y, Park Y, Kook K . Hyaluronic acid induces COX-2 expression via CD44 in orbital fibroblasts from patients with thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014; 55(11):7441-50. DOI: 10.1167/iovs.14-14873. View

19.

Matheis N, Lantz M, Grus F, Ponto K, Wolters D, Brorson H . Proteomics of Orbital Tissue in Thyroid-Associated Orbitopathy. J Clin Endocrinol Metab. 2015; 100(12):E1523-30. DOI: 10.1210/jc.2015-2976. View

20.

Vos X, Smit N, Endert E, Tijssen J, Wiersinga W . Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol (Oxf). 2008; 69(2):311-7. DOI: 10.1111/j.1365-2265.2008.03192.x. View